-Reuters
SVB Leerink Maintains Outperform on Avidity Biosciences, Lowers Price Target to $50
SVB Leerink maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and lowers the price target from $53 to $50.
Related Posts
Apple Co-Founder Steve Jobs’ Handwritten Letter To Friend Expected To Fetch Up To $300,000 In Auction
A handwritten letter by late Apple Inc.
Reported Thursday, Jan 26 ‘Disney Reorganization Looms Ahead Of First Earnings Report Since Bob Iger’s Return’ – Deadline
https://deadline.com/2023/01/disney-restructuring-layoffs-bob-iger-return-1235241668/
The initial exuberance and relief following Bob Iger’s return as Disney CEO has been replaced by anxiety as
Apple Retail Chain Once Owned By GameStop To Shut Down
Apple Inc (NASDAQ: AAPL) authorized retailer and service provider Simply Mac is reportedly ending operations and letting go of all its employees.